Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and …

S Wharton, S Calanna, M Davies… - Diabetes, Obesity …, 2022 - Wiley Online Library
Aim We evaluated gastrointestinal (GI) adverse events (AEs) with once‐weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …
被引用次数：96 相关文章

Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and …

S Wharton - 2021 - sciencehub.novonordisk.com
of the original article ‘Gastrointestinal tolerability of once- weekly semaglutide 2.4 mg in adults
with overweight o Page 1 © 2021 Novo Nordisk A/S; Further reproduction and distribution is …

Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and …

S Wharton, S Calanna, M Davies, D Dicker, B Goldman… - 2021 - figshare.le.ac.uk
AimWe evaluated gastrointestinal (GI) adverse events (AEs) with once-weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …
[PDF] sochob.cl

[PDF][PDF] Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse …

SW MD, SC MD, MD Melanie Davies, DD MD, BG MS… - 2021 - sochob.cl
Aim: We evaluated gastrointestinal (GI) adverse events (AEs) with once-weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …

Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and …

S Wharton, S Calanna, M Davies, D Dicker, B Goldman… - 2022 - pubmed.ncbi.nlm.nih.gov
Aim We evaluated gastrointestinal (GI) adverse events (AEs) with once-weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …

Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and …

S Wharton, S Calanna, M Davies, D Dicker… - Diabetes, Obesity & …, 2021 - europepmc.org
Aim We evaluated gastrointestinal (GI) adverse events (AEs) with once-weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and …

S Wharton, S Calanna, M Davies… - Diabetes, Obesity & …, 2022 - search.ebscohost.com
Aim: We evaluated gastrointestinal (GI) adverse events (AEs) with once‐weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …
[HTML] nih.gov

[HTML][HTML] Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse …

S Wharton, S Calanna, M Davies, D Dicker… - Diabetes, Obesity & …, 2022 - ncbi.nlm.nih.gov
Aim We evaluated gastrointestinal (GI) adverse events (AEs) with once‐weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …

Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and …

S Wharton, S Calanna… - Diabetes …, 2022 - utsouthwestern.elsevierpure.com
Aim: We evaluated gastrointestinal (GI) adverse events (AEs) with once-weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …
[PDF] le.ac.uk

[PDF][PDF] Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse …

SW MD, SC MD, MD Melanie Davies, DD MD, BG MS… - 2021 - figshare.le.ac.uk
Aim: We evaluated gastrointestinal (GI) adverse events (AEs) with once-weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …